<?xml version="1.0" encoding="utf-8"?>
<oembed>
  <version>1</version>
  <type>rich</type>
  <provider_name>Libsyn</provider_name>
  <provider_url>https://www.libsyn.com</provider_url>
  <height>90</height>
  <width>600</width>
  <title>Stress as the Sixth Vital Sign: Precision Medicine at Scale</title>
  <description>What if the missing link in treating autoimmune disease wasn’t a new drug—but a better way to measure stress? In this episode of Med Tech Gurus, we sit down with Dr. Andrew Holman, CEO of Inmedix and the innovator behind CloudHRV, the first FDA-cleared platform to measure stress biology with medical-grade precision .At a time when 75% of autoimmune treatments fail—costing billions and leaving patients without answers—CloudHRV delivers actionable insights in just five minutes reframing how clinicians think about chronic disease. Dr. Holman takes us inside his two-decade journey building Inmedix, from early IP strategy to securing partnerships with global pharma. Along the way, he shares lessons on leveraging licensing as a growth strategy, building a culture of innovation, and aligning science, business, and patient care in the pursuit of transformative healthcare solutions. Whether you’re a founder, investor, or clinician, this conversation will reshape how you think about precision medicine and the future of patient-centered innovation. </description>
  <author_name>Med Tech Gurus</author_name>
  <author_url>http://med-tech-gurus.libsyn.com/website</author_url>
  <html>&lt;iframe title="Libsyn Player" style="border: none" src="//html5-player.libsyn.com/embed/episode/id/39813170/height/90/theme/custom/thumbnail/yes/direction/forward/render-playlist/no/custom-color/88AA3C/" height="90" width="600" scrolling="no"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen&gt;&lt;/iframe&gt;</html>
  <thumbnail_url>https://assets.libsyn.com/secure/content/197725280</thumbnail_url>
</oembed>
